Tango Therapeutics, Inc. (TNGX)
| Market Cap | 3.32B +2,003.7% |
| Revenue (ttm) | 62.38M +48.3% |
| Net Income | -101.59M |
| EPS | -0.87 |
| Shares Out | 144.24M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,511,451 |
| Open | 23.71 |
| Previous Close | 23.48 |
| Day's Range | 22.92 - 23.91 |
| 52-Week Range | 1.03 - 28.41 |
| Beta | 1.22 |
| Analysts | Strong Buy |
| Price Target | 21.78 (-5.39%) |
| Earnings Date | May 22, 2026 |
About TNGX
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to ... [Read more]
Financial Performance
In 2025, Tango Therapeutics's revenue was $62.38 million, an increase of 48.29% compared to the previous year's $42.07 million. Losses were -$101.59 million, -22.03% less than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for TNGX stock is "Strong Buy." The 12-month stock price target is $21.78, which is a decrease of -5.39% from the latest price.
News
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that effective May 1, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors grant...
Tango Therapeutics price target raised to $40 from $24 at Stifel
Stifel raised the firm’s price target on Tango Therapeutics (TNGX) to $40 from $24 and keeps a Buy rating on the shares, citing increased conviction for the PRMT5 inhibitor +
Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat
- Matthew Gall appointed Chief Financial Officer - - Additional key appointments add expertise in clinical operations, corporate strategy and project leadership -
Canaccord starts Tango Therapeutics with Buy on PRMT5 inhibitor
Canaccord initiated coverage of Tango Therapeutics (TNGX) with a Buy rating and $30 price target Tango is a precision oncology company with a “best-in-class” PRMT5 inhibitor for MTAP-deleted cancer, t...
Tango Therapeutics initiated with a Buy at Canaccord
Canaccord initiated coverage of Tango Therapeutics (TNGX) with a Buy rating and $30 price target
Tango Therapeutics price target raised to $21 from $14 at B. Riley
B. Riley raised the firm’s price target on Tango Therapeutics (TNGX) to $21 from $14 and keeps a Buy rating on the shares. Shares have rebounded sharply despite limited new
Tango Therapeutics Transcript: Leerink Global Healthcare Conference 2026
The session highlighted progress in PRMT5 inhibitor development, with vopimetostat showing promising efficacy and safety in pancreatic cancer and ongoing combination trials with RAS inhibitors. New collaborations and a brain-penetrant compound expand the pipeline, aiming to transform treatment options.
Tango Therapeutics price target raised to $20 from $19 at Mizuho
Mizuho raised the firm’s price target on Tango Therapeutics (TNGX) to $20 from $19 and keeps an Outperform rating on the shares. The firm updated the company’s model post the
Tango Therapeutics price target raised to $24 from $15 at Stifel
Stifel analyst Laura Prendergast raised the firm’s price target on Tango Therapeutics (TNGX) to $24 from $15 and keeps a Buy rating on the shares. The firm views the “recent
Tango Therapeutics price target raised to $19 from $15 at Wedbush
Wedbush raised the firm’s price target on Tango Therapeutics (TNGX) to $19 from $15 and keeps an Outperform rating on the shares after the company reported fourth quarter financials and
Tango Therapeutics price target raised to $20 from $18 at Guggenheim
Guggenheim analyst Michael Schmidt raised the firm’s price target on Tango Therapeutics (TNGX) to $20 from $18 and keeps a Buy rating on the shares after the company reported Q4
Tango Therapeutics price target raised to $27 from $13 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Tango Therapeutics (TNGX) to $27 from $13 and keeps a Buy rating on the shares. The firm upped its probability of approval
Erasca, Tango Therapeutics enter clinical collaboration, supply agreement
Erasca (ERAS) announced a clinical trial collaboration and supply agreement, CTCSA, with Tango Therapeutics (TNGX) to evaluate Erasca’s pan-RAS molecular glue, ERAS-0015, with Tango’s PRMT5 inhibitor,...
Tango Therapeutics reports Q4 EPS (29c), consensus (33c)
“We enter 2026 with a clear focus on execution, building on the significant progress achieved across our development portfolio in 2025,” said Malte Peters, M.D., President and CEO of Tango
Tango Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Vopimetostat, a selective PRMT5 inhibitor, is advancing through pivotal trials in pancreatic and lung cancers, with strong early efficacy and safety data. Combination studies with RAS inhibitors and new CNS-penetrant candidates are progressing, supported by robust financials.
Tango Therapeutics weakness an ‘over reaction,’ says Stifel
Stifel believes Tango Therapeutics (TNGX) shares are reacting in large part due to Revolution Medicines’ (RVMD) announcement of a clinical trial collaboration to study a combination of daraxonrasib wi...
Tango Therapeutics initiated with an Outperform at Mizuho
Mizuho initiated coverage of Tango Therapeutics (TNGX) with an Outperform rating and $19 price target The firm says the company’s lead precision oncology program vopimetostat has a potential “first-in...
Tango Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Leadership transition brings continuity, with a focus on advancing vopimetostat toward regulatory approval. Key trials in pancreatic and lung cancer are progressing, with pivotal and combination data expected this year. Pipeline expansion includes TNG456 and TNG961, targeting new indications.
Tango Therapeutics price target raised to $14 from $11 at Piper Sandler
Piper Sandler raised the firm’s price target on Tango Therapeutics (TNGX) to $14 from $11 and keeps an Overweight rating on the shares. Following a flurry of updates from companies
Tango Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference
Leadership transitioned to Malte Peters, ensuring continuity as the company advances late-stage clinical development for MTAP-deleted cancers. Key milestones include pivotal trials in pancreatic cancer, combination studies with RAS inhibitors, and expansion into glioblastoma, supported by strong financials and FDA-aligned strategies.
Tango Therapeutics announces retirement of CEO Weber, Peters to succeed
Tango Therapeutics (TNGX) announced the retirement of its Chief Executive Officer, Dr. Barbara Weber, effective January 8, 2026. Dr. Weber, the company’s founding CEO, will become Executive Chair for ...
Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor
BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cance...
Tango Therapeutics appoints Sung Lee to board of directors
Tango Therapeutics (TNGX) announced the appointment of Mr. Sung Lee to the Board of Directors. Mr. Lee has over 20 years of experience in finance leadership in the biopharmaceutical and
Tango Therapeutics Appoints Sung Lee to Board of Directors
BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cance...
Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference
BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled t...